Company Guizhou Yibai Pharmaceutical Co., Ltd.

600594

CNE000001H03

Pharmaceuticals

End-of-day quote Shanghai S.E. 2026-09-21			5-day change	1st Jan Change
3.820 ^CNY	+7.30%		+4.37%	-4.02%

08-20	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-22	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Business description: Guizhou Yibai Pharmaceutical Co., Ltd.

Guizhou Yibai Pharmaceutical Co Ltd is a China-based company principally engaged in pharmaceutical industry, medical services, and big health industry businesses. The pharmaceutical industry business is mainly engaged in the research and development, production and sales of chemical drugs, traditional Chinese medicines, biological drugs and other drugs. The medical service business is mainly engaged in the operation and management of comprehensive hospitals, tumor specialty hospitals, and tumor radiotherapy centers. The big health industry business is mainly engaged in the development, research, production and sales of big health products featuring Miao medicine. The Company mainly operates its businesses in the domestic market.

Number of employees: 4,832

Sales by Activity: Guizhou Yibai Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Pharmaceutical Industry	2.96B	2.27B	2.35B	1.68B	1.45B
Medical Services	381M	457M	458M	467M	401M

See all business segments

Geographical breakdown of sales: Guizhou Yibai Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
China	3.35B	2.74B	2.82B	2.17B	1.86B

See all geographic segments

Executive Committee: Guizhou Yibai Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Ya Qi Dou CEO	Chief Executive Officer	42	2021-05-12
Xianti Zeng DFI	Director of Finance/CFO	52	2024-09-05
Zhi Wei Wang PRN	Corporate Officer/Principal	56	2019-09-16
Guang Xin Zhou IRC	Investor Relations Contact	-	-
Xian Hong Jiang DFI	Director of Finance/CFO	41	2020-03-22

See GUIZHOU YIBAI PHARMACEUTICAL CO., LTD. governance

Composition of the Board of Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Director	Title	Age	Since
Qi Ling Dou CHM	Chairman	66	2009-01-21
Zhi Wei Wang BRD	Director/Board Member	56	2011-02-20
Ya Qi Dou BRD	Director/Board Member	42	2019-01-02
Tao Jiang CHM	Chairman	46	2021-05-12
Wen Zong Peng BRD	Director/Board Member	54	2013-06-26
Xuan Chen BRD	Director/Board Member	-	2024-06-03
Liang Liang BRD	Director/Board Member	43	2025-11-25

Composition of the Board of Directors

Shareholders: Guizhou Yibai Pharmaceutical Co., Ltd.

Name	Stocks	%	Valuation
Huatai-PineBridge Fund Management Co., Ltd. 0.1451 %	1,149,100	0.1451 %	695 975 ¥
Zhong Ou Asset Management Co., Ltd 0.1226 %	970,600	0.1226 %	587 863 ¥
Guotai Asset Management Co., Ltd. 0.0803 %	636,131	0.0803 %	385 285 ¥
Xinyuan Asset Management Co., Ltd. 0.0329 %	260,900	0.0329 %	158 019 ¥
China Asset Management Co., Ltd. 0.0327 %	258,700	0.0327 %	156 687 ¥

List of GUIZHOU YIBAI PHARMACEUTICAL CO., LTD. shareholders

Company details: Guizhou Yibai Pharmaceutical Co., Ltd.

Guizhou Yibai Pharmaceutical Co., Ltd.

220-1 Baiyun Avenue

550008, Guiyang

+86 85 1847 05590

http://www.gzcci.com

address Guizhou Yibai Pharmaceutical Co., Ltd.(600594)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU YIBAI PHARMACEUTICAL CO., LTD.	+7.30%	+4.37%	-9.48%	-32.39%	417M
ELI LILLY AND COMPANY	+1.04%	+2.34%	+54.91%	+111.75%	1,028B
JOHNSON & JOHNSON	-0.19%	+1.18%	+52.94%	+66.69%	651B
ABBVIE INC.	+0.20%	+1.04%	+18.88%	+72.38%	466B
ROCHE HOLDING AG	+2.24%	+0.94%	+37.61%	+45.31%	346B
NOVARTIS AG	+0.90%	+1.95%	+18.79%	+25.27%	266B
ASTRAZENECA PLC	+0.48%	+3.34%	+11.11%	+15.38%	259B
AMGEN INC.	+1.95%	+3.06%	+37.75%	+45.93%	208B
NOVO NORDISK A/S	-7.65%	-7.28%	-33.09%	-59.52%	191B
GILEAD SCIENCES, INC.	+0.30%	+2.83%	+31.97%	+100.03%	186B
Average	+0.75%	+3.18%	+22.14%	+39.08%	360.21B
Weighted average by Cap.	+0.56%	+2.23%	+35.56%	+65.29%